Evidence-Based Guidance on New Paradigms in the Treatment of Acute Myeloid Leukemia

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for physicians, physician associates/physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with AML.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Characterize the pathophysiologic, clinical, cytogenetic, and molecular profiles that guide therapy selection for patients with AML 
  • Develop genetic testing strategies that incorporate expert guidance for all patient subgroups with AML who may benefit from targeted therapy
  • Plan evidence-based therapeutic strategies for older patients, those with comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Implement evidence-based interventions for patients with AML to manage treatment-related adverse events
  • Discuss promising novel agents in clinical development for the treatment of AML

You may also be interested in

Acute Myeloid Leukemia Patient Management Simulator
By working through a series of realistic case scenarios, you will experience how to manage a variety of AML presentations over time. As you make decisions, you will receive expert corrective mentoring from virtual colleagues to help you recognize optimal decision-making patterns.
Additional information
Supporters: 

Supported by an independent educational grant from AbbVie Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
08/23/2023
Course expires: 
08/23/2024
Cost:
$0.00

Daniel Pollyea, MD, MS
Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Arcellx: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BeiGene: Scientific Advisor
BerGenBio ASA: Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Genentech, Inc.: Scientific Advisor
Gilead Sciences, Inc.: Scientific Advisor
HiberCell Inc.: Scientific Advisor
ImmunoGen, Inc.: Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Kura Oncology, Inc.: Scientific Advisor
Magenta Therapeutics: Scientific Advisor
Medivir AB: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Qihan Biotech: Scientific Advisor
Ryvu Therapeutics: Scientific Advisor
Syndax Pharmaceuticals Inc.: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor
Teva Pharmaceutical Industries Ltd: Grant/Research Support
Zentalis Pharmaceuticals: Scientific Advisor

NCCN and CCO Staff Disclosures

None of the other planners/managers for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-23-096-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until August 23, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing